Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles

被引:43
作者
Rao, N. Hanumantha [1 ]
Babu, P. Baji [1 ]
Rajendra, L. [1 ]
Sriraman, R. [1 ]
Pang, Yuk-Ying S. [2 ]
Schiller, John T. [2 ]
Srinivasan, V. A. [1 ]
机构
[1] Indian Immunol Ltd, Ctr Res & Dev, Hyderabad 500032, Andhra Pradesh, India
[2] NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA
关键词
Cervical cancer; Prophylactic vaccine; Virus like particles; Yeast; Pseudovirus neutralization assay; CERVICAL-CANCER; HPV VACCINATION; VACCINES; DISEASES; PROMISE;
D O I
10.1016/j.vaccine.2011.07.071
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The major capsid protein (L1) of human papillomaviruses (HPV) expressed in heterologous systems assembles into virus-like particles (VLPs). We report cloning and expression of codon optimized HPV L1 genes of the two high-risk HPV types 16 and 18 in methylotropic yeast. Pichia pastoris. The VLPs produced in P. pastoris were subjected to three step purification method involving density gradient centrifugations and size exclusion chromatography. The enriched VLPs were characterized using conformation-specific monoclonal antibodies in ELISA and by transmission electron microscopy. Mice immunized with a bivalent HPV16 and HPV18 VLPs developed high serum antibody titers to both HPV types that persisted for 190 days post vaccination. Serum of mice immunized with the HPV-VLP preparations could neutralize homologous pseudoviruses in an in vitro assays. Our results demonstrate that the L1 proteins expressed in P. pastoris fold properly as evidenced by assembly into VLPs and induction of type-specific neutralizing antibody response in mice. This work constitutes a step towards developing an alternate production platform for generating an affordable HPV vaccine to meet the needs of developing countries. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7326 / 7334
页数:9
相关论文
共 37 条
  • [1] Basu P, 2009, INDIAN J MED RES, V130, P241
  • [2] Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris
    Bazan, Silvia Boschi
    Muniz Chaves, Agtha de Alencar
    Aires, Karina Araujo
    Cianciarullo, Aurora Marques
    Garcea, Robert L.
    Ho, Paulo Lee
    [J]. ARCHIVES OF VIROLOGY, 2009, 154 (10) : 1609 - 1617
  • [3] Bharadwaj M, 2009, INDIAN J MED RES, V130, P327
  • [4] Production of human papillomavirus type 16 virus-like particles in transgenic plants
    Biemelt, S
    Sonnewald, U
    Gaimbacher, P
    Willmitzer, L
    Müller, M
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (17) : 9211 - 9220
  • [5] Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3
  • [6] The humoral response to Gardasil® over four years as defined by Total IgG and competitive luminex immunoassay
    Brown, Darron R.
    Garland, Suzanne
    Ferris, Daron G.
    Joura, Elmar
    Steben, Marc
    James, Margaret
    Radley, David
    Vuocolo, Scott
    Garner, Elizabeth I. O.
    Haupt, Richard M.
    Bryan, Janine T.
    [J]. HUMAN VACCINES, 2011, 7 (02): : 230 - 238
  • [7] Buck CB, 2005, METH MOLEC MED, V119, P445
  • [8] Human papillomavirus and cervical cancer
    Burd, EM
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2003, 16 (01) : 1 - +
  • [9] Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies
    Christensen, ND
    Dillner, J
    Eklund, C
    Carter, JJ
    Wipf, GC
    Reed, CA
    Cladel, NM
    Galloway, DA
    [J]. VIROLOGY, 1996, 223 (01) : 174 - 184
  • [10] Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae
    Cook, JC
    Joyce, JG
    George, HA
    Schultz, LD
    Hurni, WM
    Jansen, KU
    Hepler, RW
    Ip, C
    Lowe, RS
    Keller, PM
    Lehman, ED
    [J]. PROTEIN EXPRESSION AND PURIFICATION, 1999, 17 (03) : 477 - 484